Most people think of depression as a problem of brain chemistry, usually serotonin. That model is incomplete. Over the past fifteen years, a different thread of research has grown steadily stronger: for a meaningful portion of patients, depression behaves less like a chemical imbalance and more like a slow immune disturbance, with the body’s inflammatory machinery stuck partway on.

This matters practically, not just academically. If your depression came with bone-deep fatigue, unrefreshing sleep, and a sense that your body feels sick as much as your mood feels low, the immune angle may describe your experience better than the serotonin story does. And a 2026 study on ketamine gives us a new, direct look at how this drug touches the immune system in people with depression.

Depression That Looks Like Inflammation

The immune system communicates through small signaling proteins called cytokines. Some of them, like interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha), are pro-inflammatory: they turn immune activity up. In healthy conditions, they spike during an infection and settle back down once the threat passes.

In a subset of people with depression, these signals stay elevated with no infection in sight. Studies have found that roughly a quarter to a third of people with major depression, and a higher proportion of those with treatment-resistant depression, show raised inflammatory markers such as IL-6 and C-reactive protein on blood tests. The more inflammation, broadly speaking, the heavier the symptoms tend to run.

You can feel why this connection makes sense if you remember the last time you had the flu. The exhaustion, the withdrawal from other people, the loss of appetite, the foggy thinking, the flattened mood—doctors call this sickness behavior, and it is driven by the same cytokines involved in inflammatory depression. The overlap is not a metaphor. The same molecular signals produce both states.

This helps explain a frustrating clinical pattern. When inflammation is a real driver of someone’s depression, a medication that only nudges serotonin levels may not reach the actual problem. The person is not failing treatment because they lack willpower or need a higher dose. The treatment is aimed at the wrong system.

For roughly a quarter to a third of people with depression, the problem is not only in the neurotransmitters. It is partly in the immune signals—and that may be why serotonin-focused drugs sometimes miss.

What the 2026 Study Measured

Researchers wanted to know what a single dose of ketamine does to the immune system of people living with depression, and whether any immune change lines up with how they feel. So they gave a single intravenous dose of ketamine (0.5 mg/kg, the standard infusion dose) or a placebo to adults with treatment-resistant depression and to healthy volunteers, then followed their immune markers over the next day.

IL-6 told the most interesting story. About four hours after the infusion, it rose—a brief, transient bump. Then, by 24 hours, it dropped significantly, settling below where it started. The drug did not simply suppress inflammation on contact. It produced a short up-and-then-down curve in a key inflammatory signal.

The researchers also saw other rapid, temporary immune changes, including reduced activation of T-cells, a core part of the adaptive immune response. The picture was one of the immune system being transiently reorganized rather than permanently flipped.

The detail that gives this study its weight is the link to mood. The immune shifts were most evident in the people whose depression actually improved after ketamine. In other words, the change in the blood and the change in how people felt moved together. That coupling is what turns a lab curiosity into a possible mechanism.

One honest caveat: this was a small study. Small samples produce signals, not certainties, and immune measurements are notoriously variable from person to person. This finding points a direction for larger trials to confirm. It does not close the question.

How This Fits With What We Already Knew

This is not the first hint that ketamine touches inflammation. Laboratory and animal research has repeatedly found that ketamine can quiet overactive microglia—the brain’s resident immune cells—and lower local levels of inflammatory cytokines. We have written in more depth about that brain-side mechanism in our article on ketamine and neuroinflammation.

What the 2026 study adds is a look at the body side of the equation, in living humans with depression, measured in the blood, and tied to real symptom change. Together, the two bodies of evidence suggest ketamine may act on inflammation both centrally (in the brain) and peripherally (in the circulating immune system), and that this is not separate from its antidepressant effect but possibly part of it.

None of this replaces ketamine’s better-established actions. The drug blocks NMDA receptors and, within hours, triggers a burst of synaptic growth driven in part by BDNF, a protein that supports the formation of new neural connections. The immune story runs alongside those mechanisms rather than instead of them. A reasonable way to hold it: ketamine appears to work on several systems at once, and for people whose depression has an inflammatory component, the immune effect may be one of the reasons it helps when other treatments have not.

Where the Stress System Comes In

Inflammation and chronic stress are tightly wound together. Sustained psychological stress drives the HPA axis—the body’s central stress-response system—to pump out cortisol. Cortisol is supposed to be anti-inflammatory, applying the brakes to immune activity. But under long-term stress, immune cells grow less responsive to cortisol’s signal, a state called glucocorticoid resistance. The brakes wear out, and inflammation keeps running even after the original stressor is gone.

This is one reason depression linked to prolonged stress, trauma, or burnout can feel so physical and so stubborn. The nervous system and the immune system are reinforcing each other. A 2026 laboratory study found that ketamine could prevent and even reverse cortisol-driven inflammatory changes in neural cells while increasing BDNF, which fits the idea that ketamine may interrupt this stress-inflammation loop at more than one point.

For people whose depression grew out of a long season of stress, this framing can be clarifying. The heaviness in the body is not imagined, and it is not a character flaw. It is, in part, a biological state—and biological states can change.

What This Means If You’re Considering Treatment

A few grounded takeaways, because research is only useful if it connects to real decisions.

If your depression has coexisted with chronic pain, the inflammatory thread may be especially relevant, since both conditions share overlapping immune pathways. We explore that overlap in ketamine for PTSD and chronic pain and on our chronic pain page.

What Treatment Looks Like at Our Clinic

Infusions at Music City Ketamine follow the dose used in the research: 0.5 mg/kg given intravenously over about 40 minutes. Marla Peterson, CRNA, administers and monitors every infusion personally. For treatment-resistant depression, we typically start with a series of six infusions over two to three weeks, matching the protocols used in the clinical studies.

During your first visit, we take a full history—not just your diagnosis, but your sleep, your energy, your physical health, any inflammatory or autoimmune conditions, and the arc of how your symptoms developed. That broader view helps us set realistic expectations and understand which parts of the picture ketamine is most likely to reach.

Walter White and Wilma, our clinic dogs, are present during sessions. For a nervous system that has been running hot for a long time, the simple presence of a calm animal can lower arousal in a way that words sometimes cannot. We serve patients in Franklin, Nashville, Brentwood, Cool Springs, and across Middle Tennessee, and we’re glad to talk through whether this fits your situation.